Mesoblast (MESO) EBITDA Margin (2016 - 2023)
Mesoblast's (MESO) quarterly EBITDA Margin came in at 55345.28% in Q2 2023, down 14267202.0% year-on-year from N/an in Q2 2022, and up 8.19% quarter-over-quarter from 60282.57% in Q1 2023.
Mesoblast (MESO) EBITDA Margin (2016 - 2023) Analysis & Trends
Mesoblast has disclosed EBITDA Margin across 8 years of filings, most recently posting 55345.28% for Q2 2023.
- EBITDA Margin for Q2 2023 came in at 55345.28%, down 14267202.0% year-over-year; the trailing twelve-month figure through Mar 2023 was 7741.24% (down 3790068.0% YoY), and the FY2025 annual result was 360.79%, changed N/A from the prior year.
- EBITDA Margin came in at 55345.28% for Q2 2023 at Mesoblast, up from 60282.57% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 349433.42% in Q2 2021 to a low of 79504.19% in Q1 2021.
- The 5-year median for EBITDA Margin is 39197.89% (2019), against an average of 6774.35%.
- Across the five-year window, EBITDA Margin jumped 34112451 bps in 2021 and slumped 26210668 bps in 2022, its largest moves.
- Mesoblast's EBITDA Margin stood at 37321.23% in 2019, then soared by 101 bps to 447.52% in 2020, then plunged by 9278 bps to 41074.56% in 2021, then decreased by 2 bps to 41919.39% in 2022, then sank by 32 bps to 55345.28% in 2023.
- The last three EBITDA Margin figures came in at 55345.28% (Q2 2023), 60282.57% (Q1 2023), and 41919.39% (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -55,345.28% |
| Mar 31, 2023 | -60,282.57% |
| Dec 31, 2022 | -41,919.39% |
| Sep 30, 2022 | -20,010.74% |
| Jun 30, 2022 | 87,326.74% |
| Mar 31, 2022 | -47,449.88% |
| Dec 31, 2021 | -41,074.56% |
| Sep 30, 2021 | -42,137.41% |
| Jun 30, 2021 | 349,433.42% |
| Mar 31, 2021 | -79,504.19% |
| Dec 31, 2020 | 447.52% |
| Sep 30, 2020 | 663.52% |
| Jun 30, 2020 | 8,308.90% |
| Mar 31, 2020 | -53,957.57% |
| Dec 31, 2019 | -37,321.23% |
| Sep 30, 2019 | -19,839.10% |
| Jun 30, 2019 | 556.89% |
| Mar 31, 2019 | -69,833.30% |
| Dec 31, 2018 | -58,452.26% |
| Sep 30, 2018 | -58,792.84% |